Advice
in the absence of a submission from the holder of the marketing authorisation:
darolutamide (Nubeqa®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice280KB (PDF)
Medicine details
- Medicine name:
- darolutamide (Nubeqa)
- SMC ID:
- SMC2940
- Indication:
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 June 2026